5 Things to Know About Aligos Therapeutics!
Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical-stage biotechnology Company announced the discontinuation of dosing in the first cohort of its candidate ALG-020572, intended for the treatment of chronic hepatitis B. The dosing was stopped after a patient experienced a serious adverse event (SAE) and a...
